Evidence map›Paper›PMID 24763226›Full record

ArticleCell cycle (Georgetown, Tex.)2014

Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.

Ying-Na Bao, Xue Cao, Dong-Hua Luo, Rui Sun, Li-Xia Peng, Lin Wang, Yong-Pan Yan, Li-Sheng Zheng, Ping Xie, Yun Cao and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Deciphering the role ofJournal of translational internal medicine · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 2 countries.

Ying-Na BaoState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China; Department of Radiotherapy; Affiliated Hospital of Inner Mongolia Medical University; Hohhot City, Inner Mongolia Autonomous Region, China.
Xue CaoState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Dong-Hua LuoDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Rui SunDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Li-Xia PengState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Lin WangDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Yong-Pan YanGencode Technologies; Saint Charles, MO USA.
Li-Sheng ZhengState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Ping XieState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Yun CaoState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Ying-Ying LiangState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Fang-Jing ZhengState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Bi-Jun HuangState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Yan-Qun XiangDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Xing LvDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Qiu-Yan ChenDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Ming-Yuan ChenDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Pei-Yu HuangDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Ling GuoDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Hai-Qiang MaiDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Xiang GuoDepartment of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Yi-Xin ZengState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China.
Chao-Nan QianState Key Laboratory of Oncology in South China; Sun Yat-sen University Cancer Center; Guangzhou, China; Department of Nasopharyngeal Carcinoma; Sun Yat-sen University Cancer Center; Guangzhou, China.
Sun Yat-sen University Cancer Center · CNSun Yat-sen University · CNState Key Laboratory of Oncology in South ChinaLindenwood University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in southern China and Southeast Asia, with the highest metastasis rate among head and neck cancers. The mechanisms underlying NPC progression remain poorly understood. Genome-wide expression profiling on 18 NPC vs. 18 noncancerous nasopharyngeal tissues together with GeneGo pathway analysis and expression verification in NPC cells and tissues revealed a potential role of urokinase-type plasminogen activator receptor (uPAR) in NPC progression, which has not been investigated in NPC. We then observed that uPAR expression is increased in poorly differentiated, highly metastatic NPC cells compared with lowly metastatic cells or differentiated NPC cells. In vitro studies demonstrated that uPAR regulates NPC cell growth, colony formation, migration, and invasion and promotes the epithelial-mesenchymal transition (EMT). Additional tumor xenograft and spontaneous metastasis experiments revealed that uPAR promotes NPC cell growth and metastasis in vivo. The JAK-STAT pathway is involved in uPAR-regulated signaling in NPC cells as determined by immunoblotting. Moreover, uPAR-mediated growth and motility is partially abolished upon treatment with the Jak1/Jak2 inhibitor INCB018424. We suppressed uPA expression in uPAR-overexpressing NPC cells and found that uPAR-mediated cellular growth and motility is not exclusively dependent on uPA. In summary, uPAR is a significant regulator of NPC progression and could serve as a promising therapeutic target.

Indexed as

Cell Growth ProcessesAdolescentAdultAgedAnimalsCarcinomaCell Line, TumorEnzyme InhibitorsEpithelial-Mesenchymal TransitionFemaleHeterograftsHumansJanus KinasesMaleMiceMice, NudeEnzyme InhibitorsJanus KinasesNitrilesPyrazolesPyrimidinesReceptors, Urokinase Plasminogen ActivatorruxolitinibSTAT Transcription Factorsgenome-wide expression profilingJAKmetastasisnasopharyngeal carcinomaSTATtumor growthuPAR

Identifiers

PMID24763226
PMCPMC4111759
OpenAlexW2046953700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.